- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05028361
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
Safety of Simultaneous Versus Sequential Administration of mRNA COVID-19 Vaccines and Quadrivalent Inactivated Influenza (IIV4) in Adults, Adolescents and Children: A Randomized Observer Blinded Study
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Emmanual B Walter, MD, MPH
- Phone Number: 919-620-5346
- Email: chip.walter@duke.edu
Study Contact Backup
- Name: Grace N Davis, MS
- Phone Number: 919-385-5786
- Email: grace.davis@duke.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- John Hopkins University
-
-
North Carolina
-
Durham, North Carolina, United States, 27709
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Persons aged ≥5 years if receiving primary two-dose mRNA COVID-19 vaccine series or persons aged ≥12 years if receiving a booster mRNA COVID-19 vaccine dose according to FDA authorization or approval and ACIP recommendation. Note: receipt of an mRNA COVID-19 vaccine within 8 hours of enrollment is permitted
*Individuals age 5-11 receiving a booster may be enrolled in the event a booster for individuals age 5-11 is authorized or approved and recommended by the ACIP.
- English or Spanish literate
- Intention of receiving influenza vaccine and COVID-19 vaccine based on ACIP-CDC guidelines
- Willing to provide written informed consent
- Intention of being available for entire study period and complete all relevant study procedures, including follow-up phone calls and clinic visits
Exclusion Criteria:
- Currently pregnant, planning to become pregnant within the first three months of the study per participant self-report or likely to be pregnant per screening criteria as defined in Section 5.1 at Visit 1
- Prior receipt of IIV4 during the respective influenza season in which they are being enrolled
- <9 years of age and recommended to receive two doses of IIV4 during the respective influenza season in which they are being enrolled
- Prior receipt of non-mRNA COVID-19 vaccine
- Documented COVID-19 infection within 6 weeks prior to enrollment confirmed by either medical history or lab testing
- History of severe allergic reaction after a previous dose of any influenza vaccine; or to an influenza vaccine component, including egg protein
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of an mRNA vaccine
- Receipt of any licensed inactivated vaccine within 2 weeks prior to enrollment in this study, receipt of any licensed live vaccine within 4 weeks prior to enrollment in this study, or receipt of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) or HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted) vaccine within 6 weeks prior to enrollment in this study or planning receipt of any vaccines following enrollment until 6 weeks after receipt of the second dose of mRNA COVID-19 vaccine
- Has an active neoplastic disease (excluding non-melanoma skin cancer or prostate cancer that is stable in the absence of therapy) or a history of any hematologic malignancy* *Participants with a history of malignancy may be included if, after previous treatment by surgical excision, chemotherapy or radiation therapy, the participant has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure
- Thrombocytopenia, bleeding disorder, or anticoagulant use contraindicating intramuscular injection (a daily aspirin may be acceptable).
Has immunosuppression as a result of an underlying illness or medications, such as antirejection/transplant regimens or immunomodulatory agents. Stable HIV disease is permitted per the following parameters:
a. Confirmed stable HIV disease defined as documented viral load <50 copies/mL and CD4 count >200 within 6 months before enrollment, and on stable antiretroviral therapy for at least 6 months
Has known hepatitis B (HBV) or hepatitis C (HBC). Stable HBV or HBC are permitted per the following parameters:
- If known HBV: confirmed inactive chronic HBV infection: HBsAg present for ≥6 months and HBeAg negative, anti-HBe positive; serum HBV DNA <2000 IU/mL; persistently normal ALT or AST levels; in those who had liver biopsy, findings that confirm absence of significant necroinflammation
- If known HCV: evidence of sustained virological response for ≥12 weeks after treatment or without evidence of HCV RNA viremia (undetectable HCV RNA)
Use of oral, parenteral, or high-dose inhaled glucocorticoids*
*For definition of high-dose inhaled glucocorticoids, reference Appendix B.
- History of Guillain-Barré syndrome
- Prior enrollment in this study during the 2021-22 flu season
Anyone who is already enrolled or plans to enroll in another clinical trial with an investigational product during the study period.*
*Per protocol, co-enrollment in observational or behavioral intervention studies are permitted at any time. An investigational product may be permitted for therapy of an illness condition that occurs during the study period e.g. COVID-19 illness.
- Hearing loss determined by the investigators to prevent successful communication over the phone
- History of myocarditis or pericarditis
- History of multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A).
- Has injury or other reason why deltoid site on both arms cannot be used for vaccinations.
- Any condition which, in the opinion of the investigators, may pose a health risk to the subject or interfere with the evaluation of the study objectives.
- Anyone who is a relative of any research study personnel.
- Anyone who is an employee of any research study personnel.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Simultaneous Vaccination Group
Subjects will receive a dose of mRNA COVID-19 vaccine (either as a study procedure or standard of care) and IIV4 at Visit 1, saline placebo at Visit 2, and mRNA COVID-19 vaccine at Visit 3 (only for participants receiving their primary series of mRNA COVID-19 vaccine.)
|
ACIP recommended vaccine
ACIP-CDC recommended vaccine
Saline Control
|
Other: Sequential Vaccination Group
Subjects will receive a dose of mRNA COVID-19 vaccine (either as a study procedure or standard of care) and saline placebo at Visit 1, IIV4 at Visit 2, and mRNA COVID-19 vaccine at Visit 3 (only for participants receiving their primary series of mRNA COVID-19 vaccine.)
|
ACIP recommended vaccine
ACIP-CDC recommended vaccine
Saline Control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Number of Participants With Moderate or More Severe Fever, Chills, Myalgia, or Arthralgia in the Simultaneous Group and the Sequential Group Following Both Vaccination Visit 1 and 2
Time Frame: Up to 7 Days Post Vaccination (combined for Visits 1 and 2)
|
Subjects will be asked to complete a memory aid to document symptoms and measure temperature daily.
|
Up to 7 Days Post Vaccination (combined for Visits 1 and 2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Moderate or More Severe Fever, Chills, Myalgia, or Arthralgia in the Simultaneous Versus the Sequential Group Following the First Vaccination Visit
Time Frame: Up to 7 Days Post Vaccination
|
Subjects will be asked to complete a memory aid to document symptoms and measure temperature daily.
|
Up to 7 Days Post Vaccination
|
Number of Participants With Moderate or More Severe Fever, Chills, Myalgia, or Arthralgia in the Simultaneous Versus Sequential Group Following the Second Vaccination Visit
Time Frame: Up to 7 Days Post Vaccination
|
Subjects will be asked to complete a memory aid to document symptoms and measure temperature daily.
|
Up to 7 Days Post Vaccination
|
Number of Participants in the Simultaneous and Sequential Vaccination Groups With Solicited Local and Systemic Reactogenicity Events According to Severity Grade After the First, Second and Third Vaccination Visit
Time Frame: Up to 7 Days Post Vaccination
|
Subjects will be asked to complete a memory aid to document symptoms and measure temperature daily.
|
Up to 7 Days Post Vaccination
|
Number of Participants With Observed Serious Adverse Events
Time Frame: 120 Days
|
120 Days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kawsar Talaat, MD, Johns Hopkins University
- Principal Investigator: Emmanuel B Walter, MD, MPH, Duke University
- Principal Investigator: Elizabeth Schlaudecker, MD, MPH, Children's Hospital Medical Center, Cincinnati
- Principal Investigator: Karen R Broder, MD, Centers for Disease Control and Prevention
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Extravasation of Diagnostic and Therapeutic Materials
- COVID-19
- Drug-Related Side Effects and Adverse Reactions
- Injection Site Reaction
Other Study ID Numbers
- Pro00109102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaRecruitingImprove Quality of LifeItaly
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Region VästmanlandUnknownHealth Related Quality of Life
-
Ain Shams UniversityCompletedHealth Related Quality of LifeEgypt
-
Institute of Oncology LjubljanaUnknownHealth-related Quality of LifeSlovenia
Clinical Trials on IIV4
-
China National Biotec Group Company LimitedPeking University; Hunan Provincial Center for Disease Control and Prevention; Guizhou Center for Disease Control and Prevention and other collaboratorsCompletedPneumonia, Pneumococcal | Influenza, HumanChina
-
Vanderbilt University Medical CenterDuke University; Centers for Disease Control and Prevention; Children's Hospital...Completed
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Sichuan Center for Disease... and other collaboratorsCompletedCovid19 | Pneumonia, Pneumococcal | Influenza, HumanChina
-
China National Biotec Group Company LimitedWuhan Institute of Biological Products Co., Ltd; Henan Center for Disease Control... and other collaboratorsActive, not recruitingPneumonia, Pneumococcal | Influenza, Human | COVID-19 PneumoniaChina
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHealthy | InfluenzaUnited States
-
China National Biotec Group Company LimitedXiangya Hospital of Central South University; Beijing Institute of Biological... and other collaboratorsRecruitingCOVID-19 | HemolysisChina
-
Protein Sciences CorporationSyneos Health; Department of Health and Human ServicesCompletedInfluenzaUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
Marshfield Clinic Research FoundationCenters for Disease Control and PreventionActive, not recruiting
-
Sanofi Pasteur, a Sanofi CompanyCompleted